Dihexa

TL;DR

Oral HGF/c-Met allosteric modulator. Valid preclinical synaptogenesis data (dendritic spine formation + maturation). The “10 million times more potent than BDNF” claim was formally retracted April 2025 (WSU data manipulation confirmed). Zero human clinical trials. FDA Category 2 ban (compounding prohibited September 2023). Prodrug Fosgonimeton failed Phase 2/3 LIFT-AD trial (2024). The 13-day half-life makes adverse event reversal practically impossible. Theoretical oncogenic risk via chronic c-Met activation is mechanistically serious and non-trivial.

Why it matters for Vitals

The HGF/c-Met axis is a legitimate neuroplasticity target — dendritic spine formation and maturation is the structural substrate of memory consolidation. Dihexa’s core mechanism is validated independently (Chinese replication, competitive antagonism proofs). However, in a wearable + coaching context, the inability to rapidly reverse adverse effects, combined with the Fosgonimeton clinical failure in humans, makes this a compound to track rather than recommend. The 13-day half-life and oncogenic risk are disqualifying for unsupervised use.

Key Facts

Status	Research-only; FDA Category 2 (compounding banned Sept 2023); WADA S0
Class	Angiotensin IV analog / oral peptidomimetic
Primary mechanism	Allosteric facilitator of HGF dimerization → c-Met phosphorylation → PI3K/Akt synaptogenesis
Key benefit	Injury-responsive synaptogenesis only; no effect in healthy subjects
Human equivalent dose	~22.7 mg/day oral (anecdotal biohacker range 10–50 mg/day)
Half-life	~13 days (IV rat) — makes adverse events practically irreversible
Main risks	Oncogenic (c-Met is a proto-oncogene); zero human safety data; 13-day half-life
Clinical evidence	Fosgonimeton (prodrug) failed LIFT-AD 2024; ATH-1105 (next-gen oral) in Phase 1 for ALS
Evidence level	Preclinical only; prodrug failed human trials

Mechanism Summary

HGF/c-Met signaling:

• Dihexa is not a direct c-Met agonist — requires endogenous HGF to be present
• Allosterically facilitates HGF dimerization → enables c-Met receptor phosphorylation
• Kd for HGF: 65 picomolar (extremely high affinity)
• Downstream: MAPK, ERK, PI3K/AKT → cell survival, anti-apoptosis, angiogenesis, synaptogenesis

Synaptogenesis:

• Rat hippocampal neurons: ~3× increase in total dendritic spines
• Increased spine-head width → mature mushroom spines (AMPAR-dense, long-term memory substrate)
• Injury/deficit-responsive only — no effect in healthy young rats at any dose

Independent validation of mechanism:

• Hinge (HGF dimerization antagonist) → completely abolishes Dihexa effects
• shRNA c-Met knockdown → Dihexa loses all efficacy
• Chinese Sun et al. 2021 (APP/PS1 mice): PI3K inhibitor wortmannin nullified all benefits

What the current evidence suggests

• Scopolamine amnesia reversal: Complete reversal of spatial learning deficits in Morris Water Maze
• Natural aging (22–26 month rats): Spatial memory restored to young-rat level
• APP/PS1 transgenic AD: ↑ surviving neurons, ↑ synaptophysin, ↓ GFAP/Iba-1, ↓ IL-1β/TNF-α, ↑ IL-10
• 6-OHDA Parkinson’s (rat): Complete motor restoration on rope hang test
• Human (Fosgonimeton): Biomarkers responded (p-tau217 ↓, P<0.01) but behavioral endpoints missed (GST composite P=0.70) — proof of mechanism without proof of efficacy

The retracted potency claim

⚠️ The “10 million times more potent than BDNF” statistic is fabricated. Both foundational WSU papers (McCoy 2013, Benoist 2014) were formally retracted April 2025. Data manipulation confirmed by WSU investigation.

What remains valid: Dihexa is a biologically active HGF allosteric modulator that induces synaptogenesis. The extreme potency claim is gone; the core mechanism is independently confirmed.

Fosgonimeton (ATH-1017) — clinical failure context

• Phosphate prodrug; water-soluble; subcutaneous; short clearance profile
• LIFT-AD (Phase 2/3, n=312, mild-to-moderate AD, 26 weeks): missed primary cognitive endpoint
• Biomarkers did respond — confirms target engagement in humans
• Failure interpretation: 26 weeks too short for structural synaptogenesis to manifest behaviorally; unexpected low placebo decline
• ATH-1105 (next-gen oral small molecule, not peptide): Phase 1 for ALS, favorable safety in healthy volunteers (May 2025)

Risks and uncertainty

• Oncogenic risk is mechanistically serious: c-Met is a recognized proto-oncogene; oncology has developed c-Met inhibitors as anti-cancer drugs. Dihexa activates the same pathway.
• 13-day half-life: if adverse effects emerge, drug cannot be rapidly cleared — this is a serious practical contraindication
• BPC-157 + TB-500 stacking is a theoretical oncogenic storm: BPC-157 is pro-angiogenic (VEGF); Dihexa provides scatter-factor (c-Met) signaling; TB-500 disrupts cell adhesion — simultaneously supplies vascular supply and motility to pre-existing micrometastases
• No human toxicology beyond short-duration rodent studies
• Grey market purity unknown

Inside this hub

The following compound-specific details stay here:

• CAS number, molecular formula, synthesis details (irrelevant for retrieval)
• Athira Pharma corporate history (not useful for Vitals reasoning)
• iPSC liver organoid applications (biotech use, not coaching-relevant)
• Fosgonimeton full trial data tables (the failure summary is sufficient)

Related notes

• HGF c-Met signaling — shared mechanism note (also relevant to ATH-1105)
• BPC-157 — risk note: stacking with Dihexa creates theoretical oncogenic combination
• TB-500 — same pro-angiogenic concern as BPC-157 in combination with Dihexa
• Noopept Semax Selank — other synaptogenesis/neurotrophin approaches with different risk profiles
• Lion’s Mane — TrkA/BDNF NGF inducer; Lion’s Mane has human RCTs (Dihexa does not); both affect neurotrophin pathways but via different mechanisms
• 9-MBC — astrocytic PI3K/Akt BDNF inducer; both are preclinical and injury-responsive; 9-MBC is dopaminergic (MAO-A + TH), Dihexa is HGF/c-Met; 9-MBC’s half-life is hours vs Dihexa’s 13 days

Cross-compound comparison: NGF/BDNF inducers in the vault

Property	Lion’s Mane	Dihexa	9-MBC
Primary mechanism	TrkA/TrkB NGF/BDNF induction (erinacines)	HGF/c-Met → PI3K/Akt synaptogenesis	Astrocytic PI3K/Akt → BDNF/GDNF release
Evidence level	High — multiple human RCTs	Low — preclinical; prodrug failed in humans	Low-moderate — rigorous preclinical, zero human RCTs
Effect in healthy subjects	Yes (6.7% processing speed gain)	No — injury/lesion-responsive only	Not clearly established
Key risk	Product standardization (erinacine content)	Oncogenic (c-Met proto-oncogene); 13-day half-life	UVA photosensitization; MAOI interactions
Human regulatory status	OTC (GRAS)	Research-only; FDA Category 2 ban	Research chemical; WADA S0
Best for	Chronic cognitive support; AD prophylaxis; sleep/HRV optimization	Experimental injury recovery only	Experimental dopaminergic repair; short-cycle research use only

References

• MDPI Brain Sciences 2076-3425/11/11/1487 — Chinese APP/PS1 validation, Sun et al. 2021 (independent)
• PMC 3533412 — Metabolically stabilized AngIV analogs PK study
• PMC 12701236 — LIFT-AD full trial results (Fosgonimeton failure)
• NCT06432647 — ATH-1105 Phase 1 ALS (2025)
• Neurology Live Sept 2024 — LIFT-AD failure announcement
• PubPeer 2021 — Data manipulation identification; WSU investigation confirmed